Biotech Values

[vinmantoo]

<Richard Adams, a former official in the FDA's generic-drug division who retired this year, agreed with the bias allegation. "Everyone closely involved saw that it was stacked and the whole direction was toward Momenta," he said. >

It depends on why Adams or anyone else felt the process was biased towards MNTA. If it was because MNTA was the only ones capable of definitively showing m-enox was equivalent to Lovenox, then it is obvious why the FDA would and should be "biased" towards them.